Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers as Potential Therapeutic Options for Pancreatic Cancer

被引：4
|
作者：
Asgharzadeh, Fereshteh [1 ]
Geraylow, Kiarash Roustai [2 ]
Khazaei, Majid [1 ,3 ]
Nassiri, Mohammadreza [4 ]
Hassanian, Seyed Mahdi [3 ,5 ]
Ferns, Gordon A. [6 ]
Avan, Amir [3 ,7 ,8 ]
机构：
[1] Mashhad Univ Med Sci, Dept Med Physiol, Fac Med, Mashhad, Razavi Khorasan, Iran
[2] Semnan Univ Med Sci, Student Res Comm, Semnan, Iran
[3] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Razavi Khorasan, Iran
[4] Ferdowsi Univ Mashhad, Res Inst Biotechnol, Recombinant Proteins Res Grp, Mashhad, Razavi Khorasan, Iran
[5] Mashhad Univ Med Sci, Fac Med, Dept Clin Biochem, Mashhad, Razavi Khorasan, Iran
[6] Brighton Sussex Med Sch, Div Med Educ, Brighton BN1 9PH, E Sussex, England
[7] Mashhad Univ Med Sci, Med Genet Res Ctr, Fac Med, Mashhad, Razavi Khorasan, Iran
[8] Mashhad Univ Med Sci, Basic Sci Res Inst, Mashhad, Razavi Khorasan, Iran
来源：
CURRENT CANCER DRUG TARGETS | 2022年 / 22卷 / 10期
基金：
美国国家科学基金会;
关键词：
Pancreatic cancer; ACE inhibitors; ARB inhibitors; renin-angiotensin system; carcinogenesis; gemcitabine; II TYPE-1 RECEPTOR; CATHEPSIN-D; BREAST-CANCER; TUMOR-GROWTH; CELL-PROLIFERATION; XENOGRAFT MODEL; LUNG-CANCER; SYSTEM; EXPRESSION; LOSARTAN;
D O I：
10.2174/1568009622666220517104411
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The renin-angiotensin system (RAS) has been reported to have a role in carcinogenesis, and therefore it may be of value as a potential therapeutic target in inhibiting tumor growth. It has been shown that inhibition of RAS via angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor (ARBs) inhibitors may have a protective effect against several malignancies. Here, we provide an overview of the potential value of the RAS pathway and targeting via ACE/ARB inhibitors in pancreatic cancer. Whilst the potential role of RAS as a target for the treatment of pancreatic cancer has been reported, the use of candesartan with gemcitabine failed to improve outcomes in pancreatic cancer. Another study of 1-3 years using ARB was found to reduce the risk of pancreatic cancer. In line with these trials, others have demonstrated that the ARBs in combination with gemcitabine might improve clinical outcomes in patients with advanced pancreatic cancer. Prospective trials are warranted to investigate this hypothesis.
引用
收藏
页码：785 / 795
页数：11
相关论文
共 50 条
  • [1] The Therapeutic Potential of Angiotensin-converting Enzyme and Angiotensin Receptor Inhibitors in the Treatment of Colorectal Cancer: Rational Strategies and Recent Progress
    Asgharzadeh, Fereshteh
    Hassanian, Seyed Mahdi
    Ferns, Gordon A.
    Khazaei, Majid
    Hasanzadeh, Malihe
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (39) : 4652 - 4658
  • [2] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: A meta-analysis
    Asgharzadeh, Fereshteh
    Hashemzehi, Milad
    Moradi-Marjaneh, Reyhaneh
    Hassanian, Seyed Mahdi
    Ferns, Gordon A.
    Khazaei, Majid
    Avan, Amir
    LIFE SCIENCES, 2020, 242
  • [3] Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for the Prevention of Migraines
    Gales, Barry J.
    Bailey, Emilee K.
    Reed, Ashley N.
    Gales, Mark A.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (02) : 360 - 366
  • [4] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis
    Lonn E.
    Current Atherosclerosis Reports, 2002, 4 (5) : 363 - 372
  • [5] Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
    Koomen, E. R.
    Herings, R. M. C.
    Guchelaar, H. J.
    Nijsten, T.
    CANCER EPIDEMIOLOGY, 2009, 33 (05) : 391 - 395
  • [6] Are angiotensin-converting enzyme inhibitors and angiotensin 2 receptor blockers teratogenic?
    Morton, A. P.
    DIABETIC MEDICINE, 2013, 30 (10) : 1263 - 1264
  • [7] Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Lung Cancer
    Helgeson, Scott A.
    Waddle, Mark R.
    Burnside, Rebecca C.
    Debella, Yalew T.
    Lee, Augustine S.
    Burger, Charles D.
    Li, Zhuo
    Johnson, Patrick W.
    Patel, Neal M.
    SOUTHERN MEDICAL JOURNAL, 2021, 114 (09) : 607 - 613
  • [8] Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 201p
    Sanchis-Gomar, Fabian
    Lavie, Carl J.
    Perez-Quilis, Carme
    Henry, Brandon M.
    Lippi, Giuseppe
    MAYO CLINIC PROCEEDINGS, 2020, 95 (06) : 1222 - 1230
  • [9] Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
    Holloway-Kew, Kara L.
    Betson, Amelia G.
    Anderson, Kara B.
    Sepetavc, Filip
    Gaston, James
    Kotowicz, Mark A.
    Liao, Wan-Hui
    Henneberg, Maciej
    Pasco, Julie A.
    CALCIFIED TISSUE INTERNATIONAL, 2022, 111 (04) : 396 - 408
  • [10] Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
    Mamdani, Muhammad
    Gomes, Tara
    Greaves, Simon
    Manji, Selina
    Juurlink, David N.
    Tadrous, Mina
    Kennedy, Sidney H.
    Antoniou, Tony
    JAMA NETWORK OPEN, 2019, 2 (10)
12345